{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:45:49Z","timestamp":1782953149655,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,7]]},"DOI":"10.7759\/cureus.80217","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T16:45:56Z","timestamp":1741365956000},"source":"Crossref","is-referenced-by-count":1,"title":["Evolution of Anti-citrullinated Protein Antibodies in Rheumatoid Arthritis Patients Under Disease-Modifying Therapy: A Prospective Cohort Study"],"prefix":"10.7759","author":[{"given":"Chaimae","family":"Charoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouchra","family":"Amine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"El Binoune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Zemrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Rostom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Bouziane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Bahiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen JS","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016, 388:2023-38. 10.1016\/S0140-6736(16)30173-8","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-018-0016","article-title":"Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies","volume":"6","author":"Guo Q","year":"2018","unstructured":"Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018, 6:1-14. 10.1038\/s41413-018-0016","journal-title":"Bone Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21114015","article-title":"Anti-citrullinated protein antibodies in patients with rheumatoid arthritis: biological effects and mechanisms of immunopathogenesis","volume":"21","author":"Wu CY","year":"2020","unstructured":"Wu CY, Yang HY, Lai JH. Anti-citrullinated protein antibodies in patients with rheumatoid arthritis: biological effects and mechanisms of immunopathogenesis. Int J Mol Sci. 2020, 21:10.3390\/ijms21114015","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/art.30537","article-title":"Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis","volume":"63","author":"van de Stadt LA","year":"2011","unstructured":"van de Stadt LA, de Koning MH, van de Stadt RJ, Wolbink G, Dijkmans BA, Hamann D, van Schaardenburg D. Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum. 2011, 63:3226-33. 10.1002\/art.30537","journal-title":"Arthritis Rheum"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033571","article-title":"Longitudinal analysis of citrullinated protein\/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression","volume":"64","author":"R\u00f6nnelid J","year":"2005","unstructured":"R\u00f6nnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, van Vollenhoven RF. Longitudinal analysis of citrullinated protein\/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis. 2005, 64:1744-9. 10.1136\/ard.2004.033571","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.148759","article-title":"Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries","volume":"70","author":"Chatzidionysiou K","year":"2011","unstructured":"Chatzidionysiou K, Lie E, Nasonov E, et al.. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011, 70:1575-80. 10.1136\/ard.2010.148759","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283369cb8","article-title":"B cells in the pathogenesis and treatment of rheumatoid arthritis","volume":"22","author":"Marston B","year":"2010","unstructured":"Marston B, Palanichamy A, Anolik JH. B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2010, 22:307-15. 10.1097\/BOR.0b013e3283369cb8","journal-title":"Curr Opin Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05186-1","article-title":"Treat-to-target strategies aiming at additional ultrasound remission is associated with better control of disease activity and less flare in rheumatoid arthritis","volume":"40","author":"Geng Y","year":"2021","unstructured":"Geng Y, Wang L, Zhang X, Ji L, Deng X, Zhang Z. Treat-to-target strategies aiming at additional ultrasound remission is associated with better control of disease activity and less flare in rheumatoid arthritis. Clin Rheumatol. 2021, 40:113-21. 10.1007\/s10067-020-05186-1","journal-title":"Clin Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm E","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008, 61:344-9. 10.1016\/j.jclinepi.2007.11.008","journal-title":"J Clin Epidemiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2021.38.183.27081","article-title":"The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies","volume":"38","author":"Eddaoudi M","year":"2021","unstructured":"Eddaoudi M, Rostom S, Hmamouchi I, et al.. The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies. Pan Afr Med J. 2021, 38:183. 10.11604\/pamj.2021.38.183.27081","journal-title":"Pan Afr Med J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.rhum.2020.10.207","article-title":"[Variation du taux d\u2019anticorps anti-peptide citrullin\u00e9 apr\u00e8s un traitement par abatacept en comparaison au rituximab et anti-TNFa]","volume":"87","author":"Hilliquin S","year":"2020","unstructured":"Hilliquin S, Herrou J, Gutermann L, et al.. [Variation du taux d\u2019anticorps anti-peptide citrullin\u00e9 apr\u00e8s un traitement par abatacept en comparaison au rituximab et anti-TNFa]. Rev Rhum. 2020, 87:120. 10.1016\/j.rhum.2020.10.207","journal-title":"Rev Rhum"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.09.011","article-title":"Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-a longitudinal analysis","volume":"46","author":"Wunderlich C","year":"2017","unstructured":"Wunderlich C, Oliviera I, Figueiredo CP, Rech J, Schett G. Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-a longitudinal analysis. Semin Arthritis Rheum. 2017, 46:709-14. 10.1016\/j.semarthrit.2016.09.011","journal-title":"Semin Arthritis Rheum"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.042648","article-title":"Update on rituximab","volume":"64 Suppl 4","author":"Eisenberg R","year":"2005","unstructured":"Eisenberg R. Update on rituximab. Ann Rheum Dis. 2005, 64 Suppl 4:iv55-7. 10.1136\/ard.2005.042648","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/1h6h71","article-title":"Changes of anti-citrullinated peptide antibodies titers after biologic treatment in patients with rheumatoid arthritis: a systematic literature review and retrospective study","volume":"41","author":"Hilliquin S","year":"2023","unstructured":"Hilliquin S, Herrou J, Gutermann L, et al.. Changes of anti-citrullinated peptide antibodies titers after biologic treatment in patients with rheumatoid arthritis: a systematic literature review and retrospective study. Clin Exp Rheumatol. 2023, 41:1417-26. 10.55563\/clinexprheumatol\/1h6h71","journal-title":"Clin Exp Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213823","article-title":"In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission","volume":"77","author":"de Moel EC","year":"2018","unstructured":"de Moel EC, Derksen VF, Trouw LA, et al.. In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission. Ann Rheum Dis. 2018, 77:1836-8. 10.1136\/annrheumdis-2018-213823","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1815-0","article-title":"In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response","volume":"21","author":"de Moel EC","year":"2019","unstructured":"de Moel EC, Derksen VF, Trouw LA, et al.. In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response. Arthritis Res Ther. 2019, 21:28. 10.1186\/s13075-019-1815-0","journal-title":"Arthritis Res Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.04.029","article-title":"Association of changes in anticitrullinated protein antibody levels with resource use and disease activity measures in rheumatoid arthritis patients a US observational cohort","volume":"41","author":"Alemao E","year":"2019","unstructured":"Alemao E, Iannaccone CK, Weinblatt ME, Shadick NA. Association of changes in anticitrullinated protein antibody levels with resource use and disease activity measures in rheumatoid arthritis patients a US observational cohort. Clin Ther. 2019, 41:1057-1065.e3. 10.1016\/j.clinthera.2019.04.029","journal-title":"Clin Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202297","article-title":"Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis","volume":"72","author":"B\u00f6hler C","year":"2013","unstructured":"B\u00f6hler C, Radner H, Smolen JS, Aletaha D. Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis. Ann Rheum Dis. 2013, 72:241-4. 10.1136\/annrheumdis-2012-202297","journal-title":"Ann Rheum Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214868","article-title":"Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status","volume":"78","author":"Boeters DM","year":"2019","unstructured":"Boeters DM, Burgers LE, Toes RE, van der Helm-van Mil A. Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status. Ann Rheum Dis. 2019, 78:1497-504. 10.1136\/annrheumdis-2018-214868","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/340487-evolution-of-anti-citrullinated-protein-antibodies-in-rheumatoid-arthritis-patients-under-disease-modifying-therapy-a-prospective-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T16:45:59Z","timestamp":1741365959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/340487-evolution-of-anti-citrullinated-protein-antibodies-in-rheumatoid-arthritis-patients-under-disease-modifying-therapy-a-prospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.80217","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,7]]}}}